Snipr Biome brings first candidate to human trial

Danish CRISPR company Snipr Biome has started a phase I study of drug candidate SNIPR001, which is designed to treat E.coli infections in the gut, and is expecting the first data toward the end of the year.
Christian Grøndahl, CEO and co-founder of Snipr Biome | Photo: Snipr Biome/PR
Christian Grøndahl, CEO and co-founder of Snipr Biome | Photo: Snipr Biome/PR
by albert rønning-andersson, translated by daniel pedersen

Copenhagen-based CRISPR company Snipr Biome has formally initiated a placebo-controlled phase I trial with a potential treatment for E. coli infections in the gut, and has dosed the first, healthy person, the company has announced in a press release on Wednesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading